View Older Stories View More Recent Stories

Sep 28, 2021 07:30AM Arrowhead Earns $10 Million Phase 1 Milestone Payment
Sep 1, 2021 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
Aug 5, 2021 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results
Jul 29, 2021 07:47AM Arrowhead Pharmaceuticals Inc. (ARWR) Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Jul 29, 2021 07:30AM Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
Jul 14, 2021 07:30AM Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 14, 2021 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results
Jul 6, 2021 07:31AM Arrowhead Pharmaceuticals (ARWR) Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of ccRCC
Jul 6, 2021 07:30AM Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Jul 2, 2021 07:32AM Arrowhead Pharmaceuticals Inc. (ARWR) Pauses ARO-ENaC Phase 1/2 Clinical Study
Jul 2, 2021 07:30AM Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
Jun 30, 2021 07:30AM Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
Jun 26, 2021 06:15AM Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
Jun 25, 2021 07:32AM Arrowhead Pharmaceuticals Inc. (ARWR) Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
Jun 25, 2021 07:30AM Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
Jun 23, 2021 07:32AM Arrowhead Pharma (ARWR) Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
Jun 23, 2021 07:30AM Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
Jun 21, 2021 07:32AM Arrowhead Pharmaceuticals (ARWR), Horizon Therapeutics (HZNP) Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 21, 2021 07:30AM Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 21, 2021 07:30AM Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Jun 3, 2021 07:30AM Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
Jun 2, 2021 07:30AM  Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
May 18, 2021 07:34AM Arrowhead Pharmaceuticals (ARWR) Earns $10 Million Option Exercise Fee
May 18, 2021 07:30AM Arrowhead Earns $10 Million Option Exercise Fee
May 12, 2021 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
May 4, 2021 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results
Apr 28, 2021 07:36AM Arrowhead (ARWR) Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
Apr 28, 2021 07:30AM Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
Apr 16, 2021 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results
Apr 15, 2021 07:31AM Arrowhead Pharmaceuticals Inc. (ARWR) Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
Apr 15, 2021 07:30AM Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
Mar 1, 2021 07:40AM Arrowhead Pharmaceuticals Inc. (ARWR) Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
Mar 1, 2021 07:30AM Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
Jan 25, 2021 07:33AM Arrowhead Pharmaceuticals Inc. (ARWR) Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
Jan 25, 2021 07:30AM Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
Jan 19, 2021 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results
Dec 7, 2020 04:10PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Nov 30, 2020 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
Nov 25, 2020 07:30AM Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda
Nov 23, 2020 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results
Nov 13, 2020 10:00AM Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020
Nov 13, 2020 09:02AM Arrowhead Pharmaceuticals Inc. (ARWR) Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease
Nov 13, 2020 09:00AM Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease
Nov 9, 2020 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
Nov 4, 2020 07:30AM Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
Nov 2, 2020 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results
Oct 8, 2020 07:32AM Takeda (TAK) and Arrowhead (ARWR) Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Oct 8, 2020 07:30AM Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Sep 30, 2020 04:01PM Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference
Sep 24, 2020 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
View More Recent Stories View Older Stories